{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:26:01Z","timestamp":1790616361219,"version":"4.1.0"},"reference-count":197,"publisher":"American Association for Cancer Research (AACR)","issue":"11","funder":[{"name":"n\/a","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title\/>\n                  <jats:p>The introduction of immunotherapy has ushered in a new era of anticancer therapy for many cancer types including melanoma. Given the increasing development of novel compounds and combinations and the investigation in earlier disease stages, the need grows for biomarker-based treatment personalization. Stage III melanoma is one of the front-runners in the neoadjuvant immunotherapy field, facilitating quick biomarker identification by its immunogenic capacity, homogeneous patient population, and reliable efficacy readout. In this review, we discuss potential biomarkers for response prediction to neoadjuvant immunotherapy, and how the neoadjuvant melanoma platform could pave the way for biomarker identification in other tumor types.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Significance:<\/jats:title>\n                  <jats:p>In accordance with the increasing rate of therapy development, the need for biomarker-driven personalized treatments grows. The current landscape of neoadjuvant treatment and biomarker development in stage III melanoma can function as a poster child for these personalized treatments in other tumors, assisting in the development of new biomarker-based neoadjuvant trials. This will contribute to personalized benefit\u2013risk predictions to identify the most beneficial treatment for each patient.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1158\/2159-8290.cd-23-0352","type":"journal-article","created":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T12:37:34Z","timestamp":1693917454000},"page":"2319-2338","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Biomarker-Driven Personalization of Neoadjuvant Immunotherapy in Melanoma"],"prefix":"10.1158","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-8431-7557","authenticated-orcid":false,"given":"Lotte L.","family":"Hoeijmakers","sequence":"first","affiliation":[{"name":"1Department of Medical Oncology, Netherlands Cancer Institute (NKI), Amsterdam, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7103-3219","authenticated-orcid":false,"given":"Irene L.M.","family":"Reijers","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Netherlands Cancer Institute (NKI), Amsterdam, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7945-5846","authenticated-orcid":false,"given":"Christian U.","family":"Blank","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Netherlands Cancer Institute (NKI), Amsterdam, the Netherlands."},{"name":"2Department of Medical Oncology, Leiden University Medical Center (LUMC), Leiden, the Netherlands."},{"name":"3Molecular Oncology and Immunology, Netherlands Cancer Institute (NKI), Amsterdam, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2023,9,5]]},"reference":[{"key":"2023110107464415200_bib1","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"2023110107464415200_bib2","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N Engl J Med"},{"key":"2023110107464415200_bib3","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1056\/NEJMoa1904059","article-title":"Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma","volume":"381","author":"Robert","year":"2019","journal-title":"N Engl J Med"},{"key":"2023110107464415200_bib4","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/S1470-2045(18)30700-9","article-title":"Nivolumab plus ipilimumab or nivolumab alone versus ipilimu\u00admab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial","volume":"19","author":"Hodi","year":"2018","journal-title":"Lancet Oncol"},{"key":"2023110107464415200_bib5","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/S1470-2045(19)30388-2","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study","volume":"20","author":"Robert","year":"2019","journal-title":"Lancet Oncol"},{"key":"2023110107464415200_bib6","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S0140-6736(20)30417-7","article-title":"Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"395","author":"Zimmer","year":"2020","journal-title":"Lancet"},{"key":"2023110107464415200_bib7","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa2005493","article-title":"Five-year analysis of adjuvant dabrafenib plus trametinib in stage III melanoma","volume":"383","author":"Dummer","year":"2020","journal-title":"N Engl J Med"},{"key":"2023110107464415200_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2019.07.001","article-title":"Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial","volume":"119","author":"Eggermont","year":"2019","journal-title":"Eur J Cancer"},{"key":"2023110107464415200_bib9","doi-asserted-by":"crossref","first-page":"EVIDoa2200214","DOI":"10.1056\/EVIDoa2200214","article-title":"Five-year analysis of adjuvant pembrolizumab or placebo in stage III melanoma","volume":"1","author":"Eggermont","year":"2022","journal-title":"NEJM Evidence"},{"key":"2023110107464415200_bib10","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/S1470-2045(20)30494-0","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial","volume":"21","author":"Ascierto","year":"2020","journal-title":"Lancet Oncol"},{"key":"2023110107464415200_bib11","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1016\/S0140-6736(22)00562-1","article-title":"Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial","volume":"399","author":"Luke","year":"2022","journal-title":"Lancet"},{"key":"2023110107464415200_bib12","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S1470-2045(15)70122-1","article-title":"Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial","volume":"16","author":"Eggermont","year":"2015","journal-title":"Lancet Oncol"},{"key":"2023110107464415200_bib13","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N Engl J Med"},{"key":"2023110107464415200_bib14","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1158\/2159-8290.CD-21-1141","article-title":"Adjuvant pembrolizumab versus IFN\u03b12b or ipilimumab in resected high-risk melanoma","volume":"12","author":"Grossmann","year":"2022","journal-title":"Cancer Discov"},{"key":"2023110107464415200_bib15","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12885-020-07538-1","article-title":"Comparative efficacy and safety of adjuvant nivolumab versus other treatments in adults with resected melanoma: a systematic literature review and network meta-analysis","volume":"21","author":"Toor","year":"2021","journal-title":"BMC Cancer"},{"key":"2023110107464415200_bib16","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1080\/21556660.2019.1649266","article-title":"An indirect treatment comparison of the efficacy of pembrolizumab versus competing regimens for the adjuvant treatment of stage III melanoma","volume":"8","author":"Lorenzi","year":"2019","journal-title":"J Drug Assess"},{"key":"2023110107464415200_bib17","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1158\/2159-8290.CD-16-0577","article-title":"Improved efficacy of neoadjuvant compared to adjuvant immunothe\u00adrapy to eradicate metastatic disease","volume":"6","author":"Liu","year":"2016","journal-title":"Cancer Discov"},{"key":"2023110107464415200_bib18","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1038\/s41591-018-0197-1","article-title":"Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma","volume":"24","author":"Amaria","year":"2018","journal-title":"Nat Med"},{"key":"2023110107464415200_bib19","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1056\/NEJMoa1716078","article-title":"Neoadjuvant PD-1 blockade in resectable lung cancer","volume":"378","author":"Forde","year":"2018","journal-title":"N Engl J Med"},{"key":"2023110107464415200_bib20","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1038\/s41591-018-0198-0","article-title":"Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma","volume":"24","author":"Blank","year":"2018","journal-title":"Nat Med"},{"key":"2023110107464415200_bib21","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1056\/NEJMoa2211437","article-title":"Neoadjuvant\u2013adjuvant or adjuvant-only pembrolizumab in advanced melanoma","volume":"388","author":"Patel","year":"2023","journal-title":"N Engl J Med"},{"key":"2023110107464415200_bib22","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41591-020-01188-3","article-title":"Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)","volume":"27","author":"Menzies","year":"2021","journal-title":"Nat Med"},{"key":"2023110107464415200_bib23","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.annonc.2023.01.004","article-title":"Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials","volume":"34","author":"Versluis","year":"2023","journal-title":"Ann Oncol"},{"key":"2023110107464415200_bib24","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/s41591-020-01211-7","article-title":"Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma","volume":"27","author":"Rozeman","year":"2021","journal-title":"Nat Med"},{"key":"2023110107464415200_bib25","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/s41591-022-01851-x","article-title":"Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial","volume":"28","author":"Reijers","year":"2022","journal-title":"Nat Med"},{"key":"2023110107464415200_bib26","doi-asserted-by":"crossref","first-page":"3945","DOI":"10.1245\/s10434-019-07274-2","article-title":"Early recurrence in completely resected IIIB and IIIC melanoma warrants restaging prior to adjuvant therapy","volume":"26","author":"Bloemendal","year":"2019","journal-title":"Ann Surg Oncol"},{"key":"2023110107464415200_bib27","doi-asserted-by":"crossref","first-page":"3694","DOI":"10.1245\/s10434-021-11236-y","article-title":"Neoadjuvant systemic therapy (NAST) in patients with melanoma: surgical considerations by the International Neoadjuvant Melanoma Consortium (INMC)","volume":"29","author":"van Akkooi","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"2023110107464415200_bib28","doi-asserted-by":"crossref","first-page":"e87705","DOI":"10.1371\/journal.pone.0087705","article-title":"Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab","volume":"9","author":"Tarhini","year":"2014","journal-title":"PLoS One"},{"key":"2023110107464415200_bib29","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1093\/annonc\/mdy226","article-title":"Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma","volume":"29","author":"Tetzlaff","year":"2018","journal-title":"Ann Oncol"},{"key":"2023110107464415200_bib30","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s40425-018-0428-5","article-title":"Neoadjuvant ipilimumab (3 mg\/kg or 10 mg\/kg) and high dose IFN-alpha2b in locally\/regionally advanced melanoma: safety, efficacy and impact on T-cell repertoire","volume":"6","author":"Tarhini","year":"2018","journal-title":"J Immunother Cancer"},{"key":"2023110107464415200_bib31","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1302369","article-title":"Nivolumab plus ipilimumab in advanced melanoma","volume":"369","author":"Wolchok","year":"2013","journal-title":"N Engl J Med"},{"key":"2023110107464415200_bib32","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s41591-019-0357-y","article-title":"A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma","volume":"25","author":"Huang","year":"2019","journal-title":"Nat Med"},{"key":"2023110107464415200_bib33","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/S1470-2045(19)30151-2","article-title":"Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial","volume":"20","author":"Rozeman","year":"2019","journal-title":"Lancet Oncol"},{"key":"2023110107464415200_bib34","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1001\/jamasurg.2021.7554","article-title":"Representativeness of the index lymph node for total nodal basin in pathologic response assessment after neoadjuvant checkpoint inhibitor therapy in patients with stage III melanoma","volume":"157","author":"Reijers","year":"2022","journal-title":"JAMA Surgery"},{"key":"2023110107464415200_bib35","doi-asserted-by":"crossref","first-page":"4195","DOI":"10.1158\/1078-0432.CCR-20-4301","article-title":"Neoadjuvant pembrolizumab and high-dose IFNa-2b in resectable regionally advanced melanoma","volume":"27","author":"Najjar","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2023110107464415200_bib36","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41586-022-05368-8","article-title":"Neoadjuvant relatlimab and nivolumab in resectable melanoma","volume":"611","author":"Amaria","year":"2022","journal-title":"Nature"},{"key":"2023110107464415200_bib37","doi-asserted-by":"crossref","first-page":"9503","DOI":"10.1200\/JCO.2022.40.16_suppl.9503","article-title":"NeoTrio: randomized trial of neoadjuvant (NAT) pembrolizumab (Pembro) alone, in sequence (SEQ) with, or concurrent (CON) with dabrafenib plus trametinib (D+T) in resectable BRAF-mutant stage III melanoma to determine optimal combination of therapy","volume":"40","author":"Long","year":"2022","journal-title":"J Clin Oncol"},{"key":"2023110107464415200_bib38","doi-asserted-by":"crossref","first-page":"e20221952","DOI":"10.1084\/jem.20221952","article-title":"IFN-\u03b3 signature enables selection of neoadjuvant treatment in patients with stage III melanoma","volume":"220","author":"Reijers","year":"2023","journal-title":"J Exp Med"},{"key":"2023110107464415200_bib39","doi-asserted-by":"crossref","first-page":"9546","DOI":"10.1200\/JCO.2023.41.16_suppl.9546","article-title":"Neoadjuvant T-VEC + nivolumab combination therapy for resectable early metastatic (stage IIIB\/C\/D-IV M1a) melanoma with injectable disease: NIVEC trial","volume":"41","author":"Zijlker","year":"2023","journal-title":"J Clin Oncol"},{"key":"2023110107464415200_bib40","doi-asserted-by":"crossref","first-page":"CT002","DOI":"10.1158\/1538-7445.AM2023-CT002","article-title":"Abstract CT002: KEYMAKER-U02 substudy 02C: neoadjuvant pembrolizumab (pembro) + vibostolimab (vibo) or gebasaxturev (geba) or pembro alone followed by adjuvant pembro for stage IIIB-D melanoma","volume":"83","author":"Dummer","year":"2023","journal-title":"Cancer Res"},{"key":"2023110107464415200_bib41","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/s41591-020-0829-0","article-title":"Learning from clinical trials of neoadjuvant checkpoint blockade","volume":"26","author":"Versluis","year":"2020","journal-title":"Nat Med"},{"key":"2023110107464415200_bib42","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/s41577-019-0224-6","article-title":"TIM3 comes of age as an inhibitory receptor","volume":"20","author":"Wolf","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"2023110107464415200_bib43","doi-asserted-by":"crossref","first-page":"e000957","DOI":"10.1136\/jitc-2020-000957","article-title":"TIGIT in cancer immunotherapy","volume":"8","author":"Chauvin","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2023110107464415200_bib44","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-SITC2022.0617","article-title":"617 Neoadjuvant intratumoral TAVO-EP (plasmid IL-12 electro gene transfer) in combination with nivolumab; preliminary clinical and biomarker data in patients with operable locoregionally advanced melanoma","volume":"10","author":"Tarhini","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2023110107464415200_bib45","doi-asserted-by":"crossref","first-page":"eabj9779","DOI":"10.1126\/scitranslmed.abj9779","article-title":"Addition of interleukin-2 overcomes resistance to neoadjuvant CTLA4 and PD1 blockade in ex vivo patient tumors","volume":"14","author":"Kaptein","year":"2022","journal-title":"Sci Transl Med"},{"key":"2023110107464415200_bib46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"2023110107464415200_bib47","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1126\/science.aaf2834","article-title":"Cancer immunology. The \u201ccancer immunogram.\u201d","volume":"352","author":"Blank","year":"2016","journal-title":"Science"},{"key":"2023110107464415200_bib48","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1056\/NEJMc1713444","article-title":"Tumor mutational burden and response rate to PD-1 inhibition","volume":"377","author":"Yarchoan","year":"2017","journal-title":"N Engl J Med"},{"key":"2023110107464415200_bib49","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","article-title":"Tumor mutational load predicts survival after immunotherapy across multiple cancer types","volume":"51","author":"Samstein","year":"2019","journal-title":"Nat Genet"},{"key":"2023110107464415200_bib50","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1158\/1535-7163.MCT-17-0386","article-title":"Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers","volume":"16","author":"Goodman","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"2023110107464415200_bib51","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1126\/science.aad0095","article-title":"Genomic correlates of response to CTLA4 blockade in metastatic melanoma","volume":"350","author":"Van Allen","year":"2015","journal-title":"Science"},{"key":"2023110107464415200_bib52","doi-asserted-by":"crossref","first-page":"683419","DOI":"10.3389\/fonc.2021.683419","article-title":"FDA-approved and emerging next generation predictive biomarkers for immune checkpoint inhibitors in cancer patients","volume":"11","author":"Wang","year":"2021","journal-title":"Front Oncol"},{"key":"2023110107464415200_bib53","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/s43018-022-00382-1","article-title":"The status of tumor mutational burden and immunotherapy","volume":"3","author":"Anagnostou","year":"2022","journal-title":"Nature Cancer"},{"key":"2023110107464415200_bib54","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1158\/1078-0432.CCR-20-3054","article-title":"Tumor mutational burden as a predictor of immunotherapy response: is more always better?","volume":"27","author":"Strickler","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2023110107464415200_bib55","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.annonc.2021.02.006","article-title":"High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types","volume":"32","author":"McGrail","year":"2021","journal-title":"Ann Oncol"},{"key":"2023110107464415200_bib56","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","article-title":"Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden","volume":"9","author":"Chalmers","year":"2017","journal-title":"Genome Med"},{"key":"2023110107464415200_bib57","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1093\/annonc\/mdz205","article-title":"Optimizing panel-based tumor mutational burden (TMB) measurement","volume":"30","author":"Budczies","year":"2019","journal-title":"Ann Oncol"},{"key":"2023110107464415200_bib58","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1158\/2326-6066.CIR-16-0143","article-title":"Targeted next generation sequencing identifies markers of response to PD-1 blockade","volume":"4","author":"Johnson","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"2023110107464415200_bib59","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13073-016-0333-9","article-title":"The impact of tumor profiling approaches and genomic data strategies for cancer precision medicine","volume":"8","author":"Garofalo","year":"2016","journal-title":"Genome Med"},{"key":"2023110107464415200_bib60","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1056\/NEJMc2031965","article-title":"The spectrum of benefit from checkpoint blockade in hypermutated tumors","volume":"384","author":"Rousseau","year":"2021","journal-title":"N Engl J Med"},{"key":"2023110107464415200_bib61","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1158\/2326-6066.CIR-19-0835","article-title":"Tumor mutation burden and structural chromosomal aberrations are not associated with T-cell density or patient survival in acral, mucosal, and cutaneous melanomas","volume":"8","author":"Edwards","year":"2020","journal-title":"Cancer Immunol Res"},{"key":"2023110107464415200_bib62","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1038\/ng.3382","article-title":"Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway","volume":"47","author":"Shain","year":"2015","journal-title":"Nat Genet"},{"key":"2023110107464415200_bib63","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/nature25187","article-title":"High response rate to PD-1 blockade in desmoplastic melanomas","volume":"553","author":"Eroglu","year":"2018","journal-title":"Nature"},{"key":"2023110107464415200_bib64","doi-asserted-by":"crossref","first-page":"e000341","DOI":"10.1136\/jitc-2019-000341","article-title":"Survival after checkpoint inhibitors for metastatic acral, mucosal and uveal melanoma","volume":"8","author":"Klemen","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2023110107464415200_bib65","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nature13988","article-title":"Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens","volume":"515","author":"Gubin","year":"2014","journal-title":"Nature"},{"key":"2023110107464415200_bib66","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","article-title":"Genetic basis for clinical response to CTLA-4 blockade in melanoma","volume":"371","author":"Snyder","year":"2014","journal-title":"N Engl J Med"},{"key":"2023110107464415200_bib67","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"key":"2023110107464415200_bib68","doi-asserted-by":"crossref","first-page":"e439","DOI":"10.1200\/JCO.2012.47.7521","article-title":"Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma","volume":"31","author":"van Rooij","year":"2013","journal-title":"J Clin Oncol"},{"key":"2023110107464415200_bib69","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1126\/science.aaf1490","article-title":"Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade","volume":"351","author":"McGranahan","year":"2016","journal-title":"Science"},{"key":"2023110107464415200_bib70","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.cell.2021.01.002","article-title":"Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition","volume":"184","author":"Litchfield","year":"2021","journal-title":"Cell"},{"key":"2023110107464415200_bib71","doi-asserted-by":"crossref","first-page":"eaaf8399","DOI":"10.1126\/science.aaf8399","article-title":"Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy","volume":"355","author":"Davoli","year":"2017","journal-title":"Science"},{"key":"2023110107464415200_bib72","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1093\/annonc\/mdx687","article-title":"Differential binding affinity of mutated peptides for MHC class I is a predictor of survival in advanced lung cancer and melanoma","volume":"29","author":"Ghorani","year":"2018","journal-title":"Ann Oncol"},{"key":"2023110107464415200_bib73","doi-asserted-by":"crossref","first-page":"100111","DOI":"10.1016\/j.iotech.2022.100111","article-title":"6P Response and survival according to the interferon-gamma (IFN-\u03b3) signature and tumor mutational burden (tmb) in the PRADO trial testing neoadjuvant ipilimumab and nivolumab in stage III melanoma","volume":"16 Suppl 1","author":"Reijers","year":"2022","journal-title":"Immuno Oncol Technol"},{"key":"2023110107464415200_bib74","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1002\/1878-0261.12748","article-title":"Role of ultraviolet mutational signature versus tumor mutation burden in predicting response to immunotherapy","volume":"14","author":"Pham","year":"2020","journal-title":"Mol Oncol"},{"key":"2023110107464415200_bib75","doi-asserted-by":"crossref","first-page":"987205","DOI":"10.3389\/fgene.2022.987205","article-title":"Two subtypes of cutaneous melanoma with distinct mutational signatures and clinico-genomic characteristics","volume":"13","author":"Kim","year":"2022","journal-title":"Front Genet"},{"key":"2023110107464415200_bib76","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1038\/emboj.2011.62","article-title":"Hydrophobicity as a driver of MHC class I antigen processing","volume":"30","author":"Huang","year":"2011","journal-title":"EMBO J"},{"key":"2023110107464415200_bib77","doi-asserted-by":"crossref","first-page":"E1754","DOI":"10.1073\/pnas.1500973112","article-title":"TCR contact residue hydrophobicity is a hallmark of immunogenic CD8+ T cell epitopes","volume":"112","author":"Chowell","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2023110107464415200_bib78","doi-asserted-by":"crossref","first-page":"7348","DOI":"10.1038\/s41467-021-26472-9","article-title":"Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma","volume":"12","author":"Vos","year":"2021","journal-title":"Nat Commun"},{"key":"2023110107464415200_bib79","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1038\/s41388-018-0245-9","article-title":"APOBEC3B and APOBEC mutational signature as potential predictive markers for immunotherapy response in non-small cell lung cancer","volume":"37","author":"Wang","year":"2018","journal-title":"Oncogene"},{"key":"2023110107464415200_bib80","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.3332\/ecancer.2021.1306","article-title":"Emerging biomarkers in metastatic urothelial carcinoma: tumour mutational burden, PD-L1 expression and APOBEC polypeptide-like signature in a patient with complete response to anti-programmed cell death protein-1 inhibitor","volume":"15","author":"Queiroz","year":"2021","journal-title":"Ecancermedicalscience"},{"key":"2023110107464415200_bib81","doi-asserted-by":"crossref","first-page":"S1389","DOI":"10.1016\/j.annonc.2022.08.016","article-title":"LBA7 Neoadjuvant immune checkpoint inhibition in locally advanced MMR-deficient colon cancer: the NICHE-2 study","volume":"33 Suppl 7","author":"Chalabi","year":"2022","journal-title":"Ann Oncol"},{"key":"2023110107464415200_bib82","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS9605","article-title":"The NADINA trial: a multicenter, randomised, phase 3 trial comparing the efficacy of neoadjuvant ipilimumab plus nivolumab with standard adjuvant nivolumab in macroscopic resectable stage III melanoma","volume":"40","author":"Lucas","year":"2022","journal-title":"J Clin Oncol"},{"key":"2023110107464415200_bib83","doi-asserted-by":"crossref","first-page":"3938","DOI":"10.1038\/s41467-022-31055-3","article-title":"Recurrent somatic mutations as predictors of immunotherapy response","volume":"13","author":"Gajic","year":"2022","journal-title":"Nat Commun"},{"key":"2023110107464415200_bib84","doi-asserted-by":"crossref","first-page":"742","DOI":"10.3390\/cancers12030742","article-title":"The role of PTEN loss in immune escape, melanoma prognosis and therapy response","volume":"12","author":"Cabrita","year":"2020","journal-title":"Cancers"},{"key":"2023110107464415200_bib85","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1038\/ng.3677","article-title":"Recurrent SERPINB3 and SERPINB4 mutations in patients who respond to anti-CTLA4 immunotherapy","volume":"48","author":"Riaz","year":"2016","journal-title":"Nat Genet"},{"key":"2023110107464415200_bib86","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1158\/2326-6066.CIR-14-0207","article-title":"Impact of NRAS mutations for patients with advanced melanoma treated with immune therapies","volume":"3","author":"Johnson","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"2023110107464415200_bib87","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.cell.2018.10.038","article-title":"Defining T cell states associated with response to checkpoint immunotherapy in melanoma","volume":"175","author":"Sade-Feldman","year":"2018","journal-title":"Cell"},{"key":"2023110107464415200_bib88","doi-asserted-by":"crossref","first-page":"5024","DOI":"10.1158\/1078-0432.CCR-16-0698","article-title":"Dynamic changes in PD-L1 expression and immune infiltrates early during treatment predict response to PD-1 blockade in melanoma","volume":"23","author":"Vilain","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2023110107464415200_bib89","doi-asserted-by":"crossref","first-page":"e004771","DOI":"10.1136\/jitc-2022-004771","article-title":"Higher proportions of CD39+ tumor-resident cytotoxic T cells predict recurrence-free survival in patients with stage III melanoma treated with adjuvant immunotherapy","volume":"10","author":"Attrill","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2023110107464415200_bib90","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1038\/s41591-018-0057-z","article-title":"A transcriptionally and functionally distinct PD-1(+) CD8(+) T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade","volume":"24","author":"Thommen","year":"2018","journal-title":"Nat Med"},{"key":"2023110107464415200_bib91","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/nm.4051","article-title":"Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients","volume":"22","author":"Gros","year":"2016","journal-title":"Nat Med"},{"key":"2023110107464415200_bib92","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.cell.2017.09.028","article-title":"Tumor and microenvironment evolution during immunotherapy with nivolumab","volume":"171","author":"Riaz","year":"2017","journal-title":"Cell"},{"key":"2023110107464415200_bib93","doi-asserted-by":"crossref","first-page":"eaah3560","DOI":"10.1126\/scitranslmed.aah3560","article-title":"Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance","volume":"9","author":"Roh","year":"2017","journal-title":"Sci Transl Med"},{"key":"2023110107464415200_bib94","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1038\/s41591-019-0522-3","article-title":"Clonal replacement of tumor-specific T cells following PD-1 blockade","volume":"25","author":"Yost","year":"2019","journal-title":"Nat Med"},{"key":"2023110107464415200_bib95","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/nrc.2017.117","article-title":"Impact of oncogenic pathways on evasion of antitumour immune responses","volume":"18","author":"Spranger","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"2023110107464415200_bib96","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.ccell.2017.04.003","article-title":"Tumor-residing Batf3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy","volume":"31","author":"Spranger","year":"2017","journal-title":"Cancer Cell"},{"key":"2023110107464415200_bib97","doi-asserted-by":"crossref","first-page":"e1546068","DOI":"10.1080\/2162402X.2018.1546068","article-title":"Batf3(+) DCs and type I IFN are critical for the efficacy of neoadjuvant cancer immunotherapy","volume":"8","author":"Liu","year":"2019","journal-title":"Oncoimmunology"},{"key":"2023110107464415200_bib98","doi-asserted-by":"crossref","first-page":"eabq6509","DOI":"10.1126\/sciimmunol.abq6509","article-title":"CXCL9 and CXCL10 bring the heat to tumors","volume":"7","author":"Reschke","year":"2022","journal-title":"Sci Immunol"},{"key":"2023110107464415200_bib99","doi-asserted-by":"crossref","first-page":"eabk1692","DOI":"10.1126\/sciimmunol.abk1692","article-title":"Multiplexed imaging mass cytometry of the chemokine milieus in melanoma characterizes features of the response to immunotherapy","volume":"7","author":"Hoch","year":"2022","journal-title":"Sci Immunol"},{"key":"2023110107464415200_bib100","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s13045-021-01080-8","article-title":"Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapy","volume":"14","author":"Tang","year":"2021","journal-title":"J Hematol Oncol"},{"key":"2023110107464415200_bib101","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1186\/s12967-018-1595-3","article-title":"Can IDO activity predict primary resistance to anti\u2013PD-1 treatment in NSCLC?","volume":"16","author":"Botticelli","year":"2018","journal-title":"J Transl Med"},{"key":"2023110107464415200_bib102","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1038\/s41591-021-01544-x","article-title":"A phase 1\/2 trial of an immune-modulatory vaccine against IDO\/PD-L1 in combination with nivolumab in metastatic melanoma","volume":"27","author":"Kjeldsen","year":"2021","journal-title":"Nat Med"},{"key":"2023110107464415200_bib103","doi-asserted-by":"crossref","first-page":"eabf9419","DOI":"10.1126\/science.abf9419","article-title":"Tertiary lymphoid structures in cancer","volume":"375","author":"Schumacher","year":"2022","journal-title":"Science"},{"key":"2023110107464415200_bib104","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/s41586-019-1914-8","article-title":"Tertiary lymphoid structures improve immunotherapy and survival in melanoma","volume":"577","author":"Cabrita","year":"2020","journal-title":"Nature"},{"key":"2023110107464415200_bib105","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/s41586-019-1922-8","article-title":"B cells and tertiary lymphoid structures promote immunotherapy response","volume":"577","author":"Helmink","year":"2020","journal-title":"Nature"},{"key":"2023110107464415200_bib106","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ejca.2021.01.036","article-title":"Tertiary lymphoid structures marker CXCL13 is associated with better survival for patients with advanced-stage bladder cancer treated with immunotherapy","volume":"148","author":"Groeneveld","year":"2021","journal-title":"Eur J Cancer"},{"key":"2023110107464415200_bib107","doi-asserted-by":"crossref","first-page":"4929","DOI":"10.1158\/0008-5472.CAN-18-0152","article-title":"Inhibition of Rspo-Lgr4 facilitates checkpoint blockade therapy by switching macrophage polarization","volume":"78","author":"Tan","year":"2018","journal-title":"Cancer Res"},{"key":"2023110107464415200_bib108","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/s41419-018-0757-9","article-title":"Proton irradiation orchestrates macrophage reprogramming through NF\u03baB signaling","volume":"9","author":"Genard","year":"2018","journal-title":"Cell Death Dis"},{"key":"2023110107464415200_bib109","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41392-021-00506-6","article-title":"Targeting macrophages in cancer immunotherapy","volume":"6","author":"Duan","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"2023110107464415200_bib110","doi-asserted-by":"crossref","first-page":"100862","DOI":"10.1016\/j.tranon.2020.100862","article-title":"Regulation of CD47 expression in cancer cells","volume":"13","author":"Huang","year":"2020","journal-title":"Transl Oncol"},{"key":"2023110107464415200_bib111","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s12967-022-03342-6","article-title":"SIRP\u03b1 and PD1 expression on tumor-associated macrophage predict prognosis of intrahepatic cholangiocarcinoma","volume":"20","author":"Yang","year":"2022","journal-title":"J Transl Med"},{"key":"2023110107464415200_bib112","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.7150\/ijbs.60782","article-title":"CD47\/SIRP\u03b1 pathway mediates cancer immune escape and immunotherapy","volume":"17","author":"Jia","year":"2021","journal-title":"Int J Biol Sci"},{"key":"2023110107464415200_bib113","doi-asserted-by":"crossref","first-page":"e0153550","DOI":"10.1371\/journal.pone.0153550","article-title":"Anti-CD47 treatment stimulates phagocytosis of glioblastoma by M1 and M2 polarized macrophages and promotes M1 polarized macrophages in vivo","volume":"11","author":"Zhang","year":"2016","journal-title":"PLoS One"},{"key":"2023110107464415200_bib114","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1080\/19420862.2017.1409319","article-title":"Elimination of tumor by CD47\/PD-L1 dual-targeting fusion protein that engages innate and adaptive immune responses","volume":"10","author":"Liu","year":"2018","journal-title":"MAbs"},{"key":"2023110107464415200_bib115","doi-asserted-by":"crossref","first-page":"6366","DOI":"10.3390\/cancers13246366","article-title":"Predictive biomarkers for outcomes of immune checkpoint inhibitors (ICIs) in melanoma: a systematic review","volume":"13","author":"Baltussen","year":"2021","journal-title":"Cancers"},{"key":"2023110107464415200_bib116","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/gene.2013.57","article-title":"Differential CTLA-4 expression in human CD4+ versus CD8+ T cells is associated with increased NFAT1 and inhibition of CD4+ proliferation","volume":"15","author":"Chan","year":"2014","journal-title":"Genes Immun"},{"key":"2023110107464415200_bib117","doi-asserted-by":"crossref","first-page":"4893","DOI":"10.1158\/1078-0432.CCR-22-0992","article-title":"PD-1T TILs as a predictive biomarker for clinical benefit to PD-1 blockade in patients with advanced NSCLC","volume":"28","author":"Hummelink","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2023110107464415200_bib118","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1172\/JCI73639","article-title":"PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors","volume":"124","author":"Gros","year":"2014","journal-title":"J Clin Invest"},{"key":"2023110107464415200_bib119","doi-asserted-by":"crossref","first-page":"608024","DOI":"10.3389\/fimmu.2020.608024","article-title":"Beyond T-cells: functional characterization of CTLA-4 expression in immune and non-immune cell types","volume":"11","author":"Oyewole-Said","year":"2020","journal-title":"Front Immunol"},{"key":"2023110107464415200_bib120","doi-asserted-by":"crossref","first-page":"108428","DOI":"10.1016\/j.clim.2020.108428","article-title":"Phenotypic characterization of tumor CTLA-4 expression in melanoma tissues and its possible role in clinical response to Ipilimumab","volume":"215","author":"Pistillo","year":"2020","journal-title":"Clin Immunol"},{"key":"2023110107464415200_bib121","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1158\/2326-6066.CIR-22-0366","article-title":"Targeting the siglec\u2013sialic acid immune axis in cancer: current and future approaches","volume":"10","author":"L\u00e4ubli","year":"2022","journal-title":"Cancer Immunol Res"},{"key":"2023110107464415200_bib122","doi-asserted-by":"crossref","first-page":"14211","DOI":"10.1073\/pnas.1409580111","article-title":"Engagement of myelomonocytic Siglecs by tumor-associated ligands modulates the innate immune response to cancer","volume":"111","author":"L\u00e4ubli","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2023110107464415200_bib123","doi-asserted-by":"crossref","first-page":"10304","DOI":"10.1073\/pnas.1608069113","article-title":"Precision glycocalyx editing as a strategy for cancer immunotherapy","volume":"113","author":"Xiao","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2023110107464415200_bib124","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1158\/1538-7445.AM2021-491","article-title":"Abstract 491: Melanoma patients with multi-Siglec ligands as profiled by HYDRA technology are refractory to PD1 blockade","volume":"81","author":"Petrone","year":"2021","journal-title":"Cancer Res"},{"key":"2023110107464415200_bib125","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1172\/JCI91190","article-title":"IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J Clin Invest"},{"key":"2023110107464415200_bib126","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s40425-018-0367-1","article-title":"Pan-cancer adaptive immune resistance as defined by the tumor inflammation signature (TIS): results from The Cancer Genome Atlas (TCGA)","volume":"6","author":"Danaher","year":"2018","journal-title":"J Immunother Cancer"},{"key":"2023110107464415200_bib127","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1186\/s12967-019-2100-3","article-title":"The tumor inflammation signature (TIS) is associated with anti\u2013PD-1 treatment benefit in the CERTIM pan-cancer cohort","volume":"17","author":"Damotte","year":"2019","journal-title":"J Transl Med"},{"key":"2023110107464415200_bib128"},{"key":"2023110107464415200_bib129","doi-asserted-by":"crossref","first-page":"e002843","DOI":"10.1136\/jitc-2021-002843","article-title":"An engineered oncolytic vaccinia virus encoding a single-chain variable fragment against TIGIT induces effective antitumor immunity and synergizes with PD-1 or LAG3 blockade","volume":"9","author":"Zuo","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2023110107464415200_bib130","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1186\/s12957-022-02810-z","article-title":"High co-expression of immune checkpoint receptors PD-1, CTLA-4, LAG3, TIM-3, and TIGIT on tumor-infiltrating lymphocytes in early-stage breast cancer","volume":"20","author":"Mollavelioglu","year":"2022","journal-title":"World J Surg Oncol"},{"key":"2023110107464415200_bib131","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/s41571-018-0007-1","article-title":"Targeting the tumour stroma to improve cancer therapy","volume":"15","author":"Valkenburg","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"2023110107464415200_bib132","doi-asserted-by":"crossref","first-page":"8509","DOI":"10.1002\/jcp.27782","article-title":"CD8+ cytotoxic T lymphocytes in cancer immunotherapy: a review","volume":"234","author":"Farhood","year":"2019","journal-title":"J Cell Physiol"},{"key":"2023110107464415200_bib133","doi-asserted-by":"crossref","first-page":"7255","DOI":"10.3390\/ijms22147255","article-title":"Profiling cancer-associated fibroblasts in melanoma","volume":"22","author":"Papaccio","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2023110107464415200_bib134","doi-asserted-by":"crossref","first-page":"880326","DOI":"10.3389\/fmed.2022.880326","article-title":"A cancer-associated fibroblasts-related six-gene panel for anti\u2013PD-1 therapy in melanoma driven by weighted correlation network analysis and supervised machine learning","volume":"9","author":"Tian","year":"2022","journal-title":"Front Med"},{"key":"2023110107464415200_bib135","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/nature25492","article-title":"TGF\u03b2 drives immune evasion in genetically reconstituted colon cancer metastasis","volume":"554","author":"Tauriello","year":"2018","journal-title":"Nature"},{"key":"2023110107464415200_bib136","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13045-019-0770-1","article-title":"Cancer-associated fibroblasts: an emerging target of anti-cancer immunotherapy","volume":"12","author":"Liu","year":"2019","journal-title":"J Hematol Oncol"},{"key":"2023110107464415200_bib137","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.cell.2014.08.007","article-title":"Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy","volume":"159","author":"Sherman","year":"2014","journal-title":"Cell"},{"key":"2023110107464415200_bib138","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/path.4727","article-title":"Anti-stromal treatment together with chemotherapy targets multiple signalling pathways in pancreatic adenocarcinoma","volume":"239","author":"Carapu\u00e7a","year":"2016","journal-title":"J Pathol"},{"key":"2023110107464415200_bib139","doi-asserted-by":"crossref","first-page":"4059","DOI":"10.1158\/0008-5472.CAN-18-0327","article-title":"LRRC15 is a novel mesenchymal protein and stromal target for antibody-drug conjugates","volume":"78","author":"Purcell","year":"2018","journal-title":"Cancer Res"},{"key":"2023110107464415200_bib140","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1158\/0008-5472.CAN-21-3734","article-title":"Exploiting LRRC15 as a novel therapeutic target in cancer","volume":"82","author":"Ray","year":"2022","journal-title":"Cancer Res"},{"key":"2023110107464415200_bib141","doi-asserted-by":"crossref","first-page":"1533033819879905","DOI":"10.1177\/1533033819879905","article-title":"Cancer-associated fibroblasts promote angiogenesis of hepatocellular carcinoma by VEGF-mediated EZH2\/VASH1 pathway","volume":"18","author":"Huang","year":"2019","journal-title":"Technol Cancer Res Treat"},{"key":"2023110107464415200_bib142","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41419-021-04461-6","article-title":"Colorectal cancer-associated fibroblasts promote metastasis by up-regulating LRG1 through stromal IL-6\/STAT3 signaling","volume":"13","author":"Zhong","year":"2021","journal-title":"Cell Death Dis"},{"key":"2023110107464415200_bib143","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1158\/2159-8290.CD-15-1545","article-title":"Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade","volume":"6","author":"Chen","year":"2016","journal-title":"Cancer Discov"},{"key":"2023110107464415200_bib144","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1084\/jem.20140559","article-title":"VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors","volume":"212","author":"Voron","year":"2015","journal-title":"J Exp Med"},{"key":"2023110107464415200_bib145","doi-asserted-by":"crossref","first-page":"3845","DOI":"10.7150\/ijbs.70958","article-title":"VEGF\/VEGFR-targeted therapy and immunotherapy in non-small cell lung cancer: targeting the tumor microenvironment","volume":"18","author":"Zhao","year":"2022","journal-title":"Int J Biol Sci"},{"key":"2023110107464415200_bib146","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/j.medj.2021.10.002","article-title":"LRG1 destabilizes tumor vessels and restricts immunotherapeutic potency","volume":"2","author":"O'Connor","year":"2021","journal-title":"Med"},{"key":"2023110107464415200_bib147","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1158\/2767-9764.CRC-23-0015","article-title":"Systemic LRG1 expression in melanoma is associated with disease progression and recurrence","volume":"3","author":"Hoefsmit","year":"2023","journal-title":"Cancer Res Commun"},{"key":"2023110107464415200_bib148","doi-asserted-by":"crossref","first-page":"S906","DOI":"10.1016\/j.annonc.2022.07.919","article-title":"793P NeoPeLe: a phase II trial of neoadjuvant (NAT) pembrolizumab (Pembro) combined with lenvatinib (Lenva) in resectable stage III melanoma","volume":"33 Suppl 7","author":"Long","year":"2022","journal-title":"Ann Oncol"},{"key":"2023110107464415200_bib149","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1038\/nrd.2016.233","article-title":"Dynamic versus static biomarkers in cancer immune checkpoint blockade: unravelling complexity","volume":"16","author":"Lesterhuis","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"2023110107464415200_bib150","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1001\/jamaoncol.2017.5332","article-title":"Association between circulating tumor DNA and pseudoprogression in patients with metastatic melanoma treated with anti-programmed cell death 1 antibodies","volume":"4","author":"Lee","year":"2018","journal-title":"JAMA Oncol"},{"key":"2023110107464415200_bib151","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1093\/annonc\/mdx026","article-title":"Circulating tumour DNA predicts response to anti\u2013PD-1 antibodies in metastatic melanoma","volume":"28","author":"Lee","year":"2017","journal-title":"Ann Oncol"},{"key":"2023110107464415200_bib152","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41586-021-03642-9","article-title":"ctDNA guiding adjuvant immunotherapy in urothelial carcinoma","volume":"595","author":"Powles","year":"2021","journal-title":"Nature"},{"key":"2023110107464415200_bib153","doi-asserted-by":"crossref","first-page":"706910","DOI":"10.3389\/fonc.2021.706910","article-title":"The prognostic value of ctDNA and bTMB on immune checkpoint inhibitors in human cancer","volume":"11","author":"Wei","year":"2021","journal-title":"Front Oncol"},{"key":"2023110107464415200_bib154","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1002\/cncr.34716","article-title":"Circulating tumor DNA-based molecular residual disease detection for treatment monitoring in advanced melanoma patients","volume":"129","author":"Eroglu","year":"2023","journal-title":"Cancer"},{"key":"2023110107464415200_bib155","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1093\/annonc\/mdx717","article-title":"Circulating tumor DNA predicts survival in patients with resected high-risk stage II\/III melanoma","volume":"29","author":"Lee","year":"2018","journal-title":"Ann Oncol"},{"key":"2023110107464415200_bib156","doi-asserted-by":"crossref","first-page":"S904","DOI":"10.1016\/j.annonc.2022.07.914","article-title":"788O Association of pre-treatment ctDNA with disease recurrence and clinical and translational factors in patients with stage IIIB-D\/IV melanoma treated with adjuvant immunotherapy (CheckMate 915)","volume":"33 Suppl 7","author":"Long","year":"2022","journal-title":"Ann Oncol"},{"key":"2023110107464415200_bib157","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1056\/NEJMoa2200075","article-title":"Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer","volume":"386","author":"Tie","year":"2022","journal-title":"N Engl J Med"},{"key":"2023110107464415200_bib158","article-title":"Detection phase II\/III trial: circulating tumor DNA\u2013guided therapy for stage IIB\/C melanoma after surgical resection","author":"Lee","journal-title":"J Clin Oncol 40, 2022 (suppl 16; abstr TPS9603)"},{"key":"2023110107464415200_bib159","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1038\/s41591-018-0134-3","article-title":"Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab","volume":"24","author":"Gandara","year":"2018","journal-title":"Nat Med"},{"key":"2023110107464415200_bib160","doi-asserted-by":"crossref","first-page":"5729","DOI":"10.1158\/1078-0432.CCR-17-1439","article-title":"Hypermutated circulating tumor DNA: correlation with res\u00adponse to checkpoint inhibitor-based immunotherapy","volume":"23","author":"Khagi","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2023110107464415200_bib161","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1001\/jamaoncol.2020.0237","article-title":"Durvalumab with or without tremelimumab vs standard chemotherapy in first-line treatment of metastatic non-small cell lung cancer: the MYSTIC phase 3 randomized clinical trial","volume":"6","author":"Rizvi","year":"2020","journal-title":"JAMA Oncol"},{"key":"2023110107464415200_bib162","doi-asserted-by":"crossref","first-page":"4993","DOI":"10.1073\/pnas.1705327114","article-title":"Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients","volume":"114","author":"Kamphorst","year":"2017","journal-title":"Proc Natl Acad Sci U S A."},{"key":"2023110107464415200_bib163","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/s41467-017-00608-2","article-title":"Predictors of responses to immune checkpoint blockade in advanced melanoma","volume":"8","author":"Jacquelot","year":"2017","journal-title":"Nat Commun"},{"key":"2023110107464415200_bib164","doi-asserted-by":"crossref","first-page":"3174","DOI":"10.4049\/jimmunol.1000749","article-title":"T-bet and eomesodermin are required for T cell-mediated antitumor immune responses","volume":"185","author":"Zhu","year":"2010","journal-title":"J Immunol"},{"key":"2023110107464415200_bib165","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1038\/s41375-021-01198-1","article-title":"EOMES is essential for antitumor activity of CD8(+) T cells in chronic lymphocytic leukemia","volume":"35","author":"Lla\u00f3-Cid","year":"2021","journal-title":"Leukemia"},{"key":"2023110107464415200_bib166","doi-asserted-by":"crossref","first-page":"e1387706","DOI":"10.1080\/2162402X.2017.1387706","article-title":"Serum exosomes as predictors of clinical response to ipilimumab in metastatic melanoma","volume":"7","author":"Tucci","year":"2018","journal-title":"Oncoimmunology"},{"key":"2023110107464415200_bib167","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.cell.2019.02.016","article-title":"Suppression of exosomal PD-L1 induces systemic anti-tumor immunity and memory","volume":"177","author":"Poggio","year":"2019","journal-title":"Cell"},{"key":"2023110107464415200_bib168","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/s41586-018-0392-8","article-title":"Exosomal PD-L1 contributes to immunosuppression and is associated with anti\u2013PD-1 response","volume":"560","author":"Chen","year":"2018","journal-title":"Nature"},{"key":"2023110107464415200_bib169","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1111\/cas.13226","article-title":"Cytokine biomarkers to predict antitumor responses to nivolumab suggested in a phase 2 study for advanced melanoma","volume":"108","author":"Yamazaki","year":"2017","journal-title":"Cancer Sci"},{"key":"2023110107464415200_bib170","doi-asserted-by":"crossref","first-page":"1758835918768238","DOI":"10.1177\/1758835918768238","article-title":"Tumour necrosis factor, interferon-gamma and interleukins as predictive markers of antiprogrammed cell-death protein-1 treatment in advanced non-small cell lung cancer: a pragmatic approach in clinical practice","volume":"10","author":"Boutsikou","year":"2018","journal-title":"Ther Adv Med Oncol"},{"key":"2023110107464415200_bib171","doi-asserted-by":"crossref","first-page":"e000842","DOI":"10.1136\/jitc-2020-000842","article-title":"Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition","volume":"8","author":"Laino","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2023110107464415200_bib172","doi-asserted-by":"crossref","first-page":"104235","DOI":"10.1016\/j.ebiom.2022.104235","article-title":"Circulating inflammatory proteins associate with response to immune checkpoint inhibition therapy in patients with advanced melanoma","volume":"83","author":"Rossi","year":"2022","journal-title":"eBioMedicine"},{"key":"2023110107464415200_bib173","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/s41591-020-0860-1","article-title":"High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade","volume":"26","author":"Yuen","year":"2020","journal-title":"Nat Med"},{"key":"2023110107464415200_bib174","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.3389\/fonc.2019.01223","article-title":"IL-6 and IL-8 are linked with myeloid-derived suppressor cell accumulation and correlate with poor clinical outcomes in melanoma patients","volume":"9","author":"Tobin","year":"2019","journal-title":"Front Oncol"},{"key":"2023110107464415200_bib175","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/s41591-020-0856-x","article-title":"Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors","volume":"26","author":"Schalper","year":"2020","journal-title":"Nat Med"},{"key":"2023110107464415200_bib176","doi-asserted-by":"crossref","first-page":"670391","DOI":"10.3389\/fimmu.2021.670391","article-title":"The role of cytokines in predicting the response and adverse events related to immune checkpoint inhibitors","volume":"12","author":"Wang","year":"2021","journal-title":"Front Immunol"},{"key":"2023110107464415200_bib177","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ccell.2022.04.004","article-title":"Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity","volume":"40","author":"Hailemichael","year":"2022","journal-title":"Cancer Cell"},{"key":"2023110107464415200_bib178","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s40425-015-0081-1","article-title":"Baseline circulating IL-17 predicts toxicity while TGF-\u03b21 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma","volume":"3","author":"Tarhini","year":"2015","journal-title":"J Immunother Cancer"},{"key":"2023110107464415200_bib179","doi-asserted-by":"crossref","first-page":"4121","DOI":"10.1158\/1078-0432.CCR-22-0404","article-title":"Baseline serum autoantibody signatures predict recurrence and toxicity in melanoma patients receiving adjuvant immune checkpoint blockade","volume":"28","author":"Johannet","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2023110107464415200_bib180","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3349\/ymj.2007.48.1.11","article-title":"The HLA system: genetics, immunology, clinical testing, and clinical implications","volume":"48","author":"Choo","year":"2007","journal-title":"Yonsei Med J"},{"key":"2023110107464415200_bib181","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1126\/science.aao4572","article-title":"Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy","volume":"359","author":"Chowell","year":"2018","journal-title":"Science"},{"key":"2023110107464415200_bib182","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.cell.2017.10.001","article-title":"Allele-specific HLA loss and immune escape in lung cancer evolution","volume":"171","author":"McGranahan","year":"2017","journal-title":"Cell"},{"key":"2023110107464415200_bib183","doi-asserted-by":"crossref","first-page":"636568","DOI":"10.3389\/fimmu.2021.636568","article-title":"Cancer immune evasion through loss of MHC class I antigen presentation","volume":"12","author":"Dhatchinamoorthy","year":"2021","journal-title":"Front Immunol"},{"key":"2023110107464415200_bib184","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1038\/s41467-017-01062-w","article-title":"Resistance to checkpoint blockade therapy through inactivation of antigen presentation","volume":"8","author":"Sade-Feldman","year":"2017","journal-title":"Nat Commun"},{"key":"2023110107464415200_bib185","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of cancer: new dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov"},{"key":"2023110107464415200_bib186","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1186\/s12967-022-03512-6","article-title":"Molecular mimicry between tumor associated antigens and microbiota-derived epitopes","volume":"20","author":"Ragone","year":"2022","journal-title":"J Transl Med"},{"key":"2023110107464415200_bib187","first-page":"47","article-title":"Neoadjuvant therapy for melanoma: new and evolving concepts","volume":"20","author":"Erstad","year":"2022","journal-title":"Clin Adv Hematol Oncol"},{"key":"2023110107464415200_bib188","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/s41591-021-01655-5","article-title":"Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer","volume":"28","author":"Derosa","year":"2022","journal-title":"Nat Med"},{"key":"2023110107464415200_bib189","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1126\/science.aan4236","article-title":"Gut microbiome modulates response to anti\u2013PD-1 immunotherapy in melanoma patients","volume":"359","author":"Gopalakrishnan","year":"2018","journal-title":"Science"},{"key":"2023110107464415200_bib190","doi-asserted-by":"crossref","first-page":"e1568812","DOI":"10.1080\/2162402X.2019.1568812","article-title":"Antibiotics are associated with decreased progression-free survival of advanced melanoma patients treated with immune checkpoint inhibitors","volume":"8","author":"Elkrief","year":"2019","journal-title":"Oncoimmunology"},{"key":"2023110107464415200_bib191","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.aan3706","article-title":"Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors","volume":"359","author":"Routy","year":"2018","journal-title":"Science"},{"key":"2023110107464415200_bib192","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/annonc\/mdy103","article-title":"Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer","volume":"29","author":"Derosa","year":"2018","journal-title":"Ann Oncol"},{"key":"2023110107464415200_bib193","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1001\/jamaoncol.2019.2785","article-title":"Association of prior antibiotic treatment with survival and response to immune checkpoint inhibitor therapy in patients with cancer","volume":"5","author":"Pinato","year":"2019","journal-title":"JAMA Oncol"},{"key":"2023110107464415200_bib194","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1038\/s41591-022-01965-2","article-title":"Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome","volume":"28","author":"Simpson","year":"2022","journal-title":"Nat Med"},{"key":"2023110107464415200_bib195","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/s41591-022-01695-5","article-title":"Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma","volume":"28","author":"Lee","year":"2022","journal-title":"Nat Med"},{"key":"2023110107464415200_bib196","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/s41571-023-00760-3","article-title":"Personalizing neoadjuvant immune-checkpoint inhibition in patients with melanoma","volume":"20","author":"Lucas","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"2023110107464415200_bib197","doi-asserted-by":"crossref","first-page":"e001352","DOI":"10.1136\/jitc-2020-001352","article-title":"Rationalizing the pathway to personalized neoadjuvant immunotherapy: the Lombard Street approach","volume":"8","author":"Versluis","year":"2020","journal-title":"J Immunother Cancer"}],"container-title":["Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/doi\/10.1158\/2159-8290.CD-23-0352\/3362091\/cd-23-0352.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/13\/11\/2319\/3378553\/2319.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/13\/11\/2319\/3378553\/2319.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T08:26:46Z","timestamp":1698827206000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/13\/11\/2319\/729842\/Biomarker-Driven-Personalization-of-Neoadjuvant"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,5]]},"references-count":197,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,9,5]]},"published-print":{"date-parts":[[2023,11,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2159-8290.cd-23-0352","relation":{},"ISSN":["2159-8274","2159-8290"],"issn-type":[{"value":"2159-8274","type":"print"},{"value":"2159-8290","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,5]]}}}